Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 43 results.
User Information
Export Records
  1. 1.   A comparison of 18F-DCFPyL, 18F-NaF and 18F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer
  2. Fourquet, Aloÿse; Rosenberg, Adrian; Mena, Esther; Shih, Joanna J; Turkbey, Baris; Blain, Maxime; Bergvall, Ethan; Lin, Frank I; Adler,Stephen; Lim, Ilhan; Madan, Ravi A; Karzai, Fatima; Gulley, James L; Dahut, William L; Wood, Bradford J; Chang, Richard; Levy, Elliot; Choyke, Peter L; Lindenberg, Liza
  3. Journal of Nuclear Medicine : official publication, Society of Nuclear Medicine. 2021, Sep 02; 63(5): 735-741.
  1. 2.   Sodium Fluoride-18 and Radium-223 Dichloride Uptake Colocalize in Osteoblastic Mouse Xenograft Tumors
  2. Phelps, Tim E.; Roy, Jyoti; Green, Michael V.; Seidel,Jurgen; Baidoo, Kwamena E.; Adler,Stephen; Edmondson,Elijah; Butcher,Donna; Matta,Jennifer; Ton, Anita T.; Wong, Karen; Huang, Shan; Ren, Ling; LeBlanc, Amy K.; Choyke, Peter L.; Jagoda, Elaine M.
  3. Cancer biotherapy & radiopharmaceuticals. 2021, Mar; 36(2): 133-142.
  1. 3.   Antibody-drug conjugates for cancer
  2. Chau, Cindy H.; Steeg,Pat; Figg, William D.
  3. Lancet (London, England). 2019, Aug 31; 394(10200): 793-804.
  1. 4.   KIT Suppresses BRAF(V600E)-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling
  2. Neiswender, James V.; Kortum, Robert L.; Bourque, Caitlin; Kasheta, Melissa; Zon, Leonard I.; Morrison, Deborah; Ceol, Craig J.
  3. Cancer Research. 2017, Nov 01; 77(21): 5820-5830.
  1. 5.   HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors
  2. Zielinski, R.; Lyakhov, I.; Hassan, M.; Kuban, M.; Shafer-Weaver, K.; Gandjbakhche, A.; Capala, J.
  3. Clinical Cancer Research. 2011, Aug; 17(15): 5071-5081.
  1. 6.   Pharmacogenomics and cancer stem cells: a changing landscape?
  2. Crea, F.; Duhagon, M. A.; Farrar, W. L.; Danesi, R.
  3. Trends in Pharmacological Sciences. 2011, Aug; 32(8): 487-494.
  1. 7.   CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity
  2. Shirota, H.; Klinman, D. M.
  3. Cancer Immunology Immunotherapy. 2011, May; 60(5): 659-669.
  1. 8.   Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas
  2. Kummar, S.; Gutierrez, M. E.; Chen, A.; Turkbey, I. B.; Allen, D.; Horneffer, Y. R.; Juwara, L.; Cao, L.; Yu, Y. K.; Kim, Y. S.; Trepel, J.; Chen, H.; Choyke, P.; Melillo, G.; Murgo, A. J.; Collins, J.; Doroshow, J. H.
  3. European Journal of Cancer. 2011, May; 47(7): 997-1005.
  1. 9.   A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
  2. Kelly, R. J.; Draper, D.; Chen, C. C.; Robey, R. W.; Figg, W. D.; Piekarz, R. L.; Chen, X. H.; Gardner, E. R.; Balis, F. M.; Venkatesan, A. M.; Steinberg, S. M.; Fojo, T.; Bates, S. E.
  3. Clinical Cancer Research. 2011, Feb; 17(3): 569-580.
  1. 10.   Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells
  2. Mathews, L. A.; Hurt, E. M.; Zhang, X. H.; Farrar, W. L.
  3. Molecular Cancer. 2010, Oct; 9: 17.
  1. 11.   Monitoring Drug-Induced gamma H2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells
  2. Wang, L. H.; Pfister, T. D.; Parchment, R. E.; Kummar, S.; Rubinstein, L.; Evrard, Y. A.; Gutierrez, M. E.; Murgo, A. J.; Tomaszewski, J. E.; Doroshow, J. H.; Kinders, R. J.
  3. Clinical Cancer Research. 2010, Feb; 16(3): 1073-1084.
  1. 12.   Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone Marrow
  2. Salcedo, R.; Hixon, J. A.; Stauffer, J. K.; Jalah, R.; Brooks, A. D.; Khan, T.; Dai, R. M.; Scheetz, L.; Lincoln, E.; Back, T. C.; Powell, D.; Hurwitz, A. A.; Sayers, T. J.; Kastelein, R.; Pavlakis, G. N.; Felber, B. K.; Trinchieri, G.; Wigginton, J.
  3. Journal of Immunology. 2009 182(7): 4328-4338.
  1. 13.   Phenotype and functional characterization of long-term gp100-specific memory CD8(+) T cells in disease-free melanoma patients before and after boosting immunization
  2. Walker, E. B.; Haley, D.; Petrausch, U.; Floyd, K.; Miller, W.; Sanjuan, N.; Alvord, G.; Fox, B. A.; Urba, W. J.
  3. Clinical Cancer Research. 2008 14(16): 5270-5283.
  1. 14.   Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer
  2. Aragon-Ching, J. B.; Gillespie, J.; Price, D. K.; Chuaqui, R.; Rodriguez-Canales, J.; Steinberg, S. M.; Dahut, W. L.; Figg, W. D.
  3. Bju International. 2007, Dec; 100(6): 1245-1248.
  1. 15.   Upregulation of CTLA-4 by HIV-specific CD4(+) T cells correlates with disease progression and defines a reversible immune dysfunction
  2. Kaufmann, D. E.; Kavanagh, D. G.; Pereyra, F.; Zaunders, J. J.; Mackey, E. W.; Miura, T.; Palmer, S.; Brockman, M.; Rathod, A.; Piechocka-Trocha, A.; Baker, B.; Zhu, B.; Le Gall, S.; Waring, M. T.; Ahern, R.; Moss, K.; Kelleher, A. D.; Coffin, J. M.; Freeman, G. J.; Rosenberg, E. S.; Walker, B. D.
  3. Nature Immunology. 2007, Nov; 8(11): 1246-1254.
  1. 16.   CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques
  2. Hryniewicz, A.; Boasso, A.; Edghill-Smith, Y.; Vaccari, M.; Fuchs, D.; Venzon, D.; Nacsa, J.; Betts, M. R.; Tsai, W. P.; Heraud, J. M.; Beer, B.; Blanset, D.; Chougnet, C.; Lowy, I.; Shearer, G. M.; Franchini, G.
  3. Blood. 2006, Dec; 108(12): 3834-3842.
  1. 17.   Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors
  2. Yazawa, H.; Murakami, T.; Li, H. M.; Back, T.; Kurosaka, K.; Suzuki, Y.; Shorts, L.; Akiyama, Y.; Maruyama, K.; Parsoneault, E.; Wiltrout, R. H.; Watanabe, M.
  3. Cancer Gene Therapy. 2006, Nov; 13(11): 993-1001.
  1. 18.   Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model
  2. He, H.; Wisner, P.; Yang, G. J.; Hu, H. M.; Haley, D.; Miller, W.; O'Hara, A.; Alvord, W. G.; Clegg, C. H.; Fox, B. A.; Urba, W. J.; Walker, E. B.
  3. Journal of Translational Medicine. 2006, Jun; 4
  1. 19.   Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Powell, D.; Lockett, S.; Arnold, A. C.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunology. 2006, MAY 15; 176(10): 6302-6312.
  1. 20.   Carbohydrate array analysis of anti-Tn antibodies and lectins reveals unexpected specificities: Implications for diagnostic and vaccine development
  2. Manimala, J. C.; Li, Z. T.; Jain, A.; VedBrat, S.; Gildersleeve, J. C.
  3. Chembiochem. 2005, DEC; 6(12): 2229-2241.
  1. 21.   Overexpression of LAMP3/TSC403/DC-LAMP promotes metastasis in uterine cervical cancer
  2. Kanao, H.; Enomoto, T.; Kimura, T.; Fujita, M.; Nakashima, R.; Ueda, Y.; Ueno, Y.; Miyatake, T.; Yoshizaki, T.; Buzard, G. S.; Tanigami, A.; Yoshino, K.; Murata, Y.
  3. Cancer Research. 2005, OCT 1; 65(19): 8640-8645.
  1. 22.   Expression of hypoxia-inducible carbonic anhydrases in brain tumors
  2. Proescholdt, M. A.; Mayer, C.; Kubitza, M.; Schubert, T.; Liao, S. Y.; Stanbridge, E. J.; Ivanov, S.; Oldfield, E. H.; Brawanski, A.; Merrill, M. J.
  3. Neuro-Oncology. 2005, OCT; 7(4): 465-475.
  1. 23.   In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative
  2. Hollingshead, M.; Alley, M.; Burger, A. M.; Borgel, S.; Pacula-Cox, C.; Fiebig, H. H.; Sausville, E. A.
  3. Cancer Chemotherapy and Pharmacology. 2005, AUG; 56(2): 115-125.
  1. 24.   In vivo hydrodynamic delivery of cDNA encoding IL-2: Rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells
  2. Ortaldo, J. R.; Winkler-Pickett, R. T.; Bere, E. W.; Watanabe, M.; Murphy, W. J.; Wiltrout, R. H.
  3. Journal of Immunology. 2005, JUL 15; 175(2): 693-699.
  1. 25.   STRA13 expression and subcellular localisation in normal and tumour tissues: implications for use as a diagnostic and differentiation marker
  2. Ivanova, A.; Liao, S. Y.; Lerman, M. I.; Ivanov, S.; Stanbridge, E. J.
  3. Journal of Medical Genetics. 2005, JUL; 42(7): 565-576.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel